-
New Forum Software Installed (Still a few issues but reopening the forum) More details.
leronlimab
-
Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome, 2022, Yang et al
In an exploratory trial treating “long COVID” with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of...- rvallee
- Thread
- ccr5 immunology leronlimab long covid red blood cells
- Replies: 8
- Forum: Long Covid research